Novo Nordisk Secures Landmark US Approval for Awiqli®, First Once-Weekly Basal Insulin
The U.S. Food and Drug Administration (FDA) has granted its approval for Awiqli® injection, a 700 units/mL formulation. This product stands as the inaugural an…
The U.S. Food and Drug Administration (FDA) has granted its approval for Awiqli® injection, a 700 units/mL formulation. This product stands as the inaugural and currently sole long-acting basal insulin treatment designed for once-weekly administration. Its authorization is for use as an adjunct to diet and exercise, with the objective of improving...
For investors monitoring Novo Nordisk (NVO), our quantitative analysis indicates an RS Score of 65.70, positioning it in the 36.64th percentile within both its country and sector. The stock exhibits robust performance in key areas, with strong section scores in Valuation (96.40), Growth (95.54), and Profitability (96.05). Conversely, Momentum (11.59) and EPS Revisions (64.00) currently present weaker scores. Want to discover which stocks rank the highest? Start your free 7-day trial at rankedstocks.com.